Big Pharma doesn't know NP exists. Unless you can find anything abut big Pharma even mentioning CYDY and NP. If they do know he exists, they know Leronlimab is a threat to their potential market share.
Big Pharma does not like having small caps in the game. If they have something that will make money, they will take it over. Its true, the quicker the BO, the less value shareholders will get. Depends on how patient shareholders want to be.
Market Data 
Markets 
AI
